Skip to content

Study · Randomized controlled trial · n = 40 · 2002

2 results

Intravenous glucagon: does it optimize evaluation of the gastrointestinal tract on helical CT?

Eisenstat RS, Gold BM, Goffner L, Fruauff AA, Pollack S, Katz DS

Clinical imaging1 Nov 2002

PMID12427437 (opens in a new tab)DOI10.1016/s0899-7071(02)00486-2 (opens in a new tab)PepBankPUB-12427437
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In outpatients, intravenous glucagon did not significantly improve qualitative bowel evaluation compared with no glucagon.

    In plain wordsIn outpatients, intravenous glucagon did not significantly change qualitative bowel CT results compared with no glucagon.

    Peptide
    Glucagon
    Outcome
    No significant changeQualitative bowel evaluation on helical CT
    Study

    n = 40

    Comparator
    no glucagon
    Outcome group
    Diagnostic Imaging Quality · Gastrointestinal
    Studied dose
    1 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in qualitative or quantitative data for the two groups.
    3 context sentences
    Summary · context
    Three radiologists evaluated the bowel using a qualitative score and mean scores for each bowel level were compared.
    Summary · context
    Forty outpatients were randomized into two groups of 20.
    Summary · context
    Twenty patients received 1 mg of intravenous glucagon and the other 20 did not.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In outpatients, intravenous glucagon did not significantly change quantitative bowel measurements compared with no glucagon.

    In plain wordsIn outpatients, intravenous glucagon did not significantly change bowel diameter measurements compared with no glucagon.

    Peptide
    Glucagon
    Outcome
    No significant changeQuantitative bowel diameter on helical CT
    Study

    n = 40

    Comparator
    no glucagon
    Outcome group
    Diagnostic Imaging Quality · Gastrointestinal
    Studied dose
    1 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in qualitative or quantitative data for the two groups.
    3 context sentences
    Summary · context
    A different radiologist measured the maximal diameter of bowel at seven levels.
    Summary · context
    Forty outpatients were randomized into two groups of 20.
    Summary · context
    Twenty patients received 1 mg of intravenous glucagon and the other 20 did not.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.